Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms

Pharmacogenomics. 2015;16(3):217-25. doi: 10.2217/pgs.14.160.

Abstract

Aim: This study attempted to identify predictors of S-warfarin clearance (CL[S]) and to make a pharmacokinetic evaluation of genotype-based dosing algorithms in African-Americans.

Methods: Using plasma S-warfarin concentration (Cp[S]) at a steady state and eight SNPs previously shown to influence warfarin dose in African-Americans, CL(S) and its predictors were estimated by population pharmacokinetic analysis in 60 African-Americans. The time courses of Cp(S) following either the loading dose or maintenance dose were simulated using the population pharmacokinetic estimates.

Results: CYP2C9*8 and body surface area or body weight were predictors of CL(S) (-30 and -5% per -0.1 m(2)/-10 kg reduction in CL[S], respectively) in African-Americans. Simulations of Cp(S) showed that Cp(S) at steady state was 1.4-times higher in patients with CYP2C9*8 than in those with CYP2C9*1/*1, irrespective of the algorithm for loading dose or maintenance dose.

Conclusion: African-Americans possess independent predictors of CL(S), possibly leading to a prediction error of any dosing algorithm that excludes African-specific variant(s). Original submitted 3 September 2014; Revision submitted 3 November 2014.

Keywords: African–American; CYP2C9*8; genotype; pharmacokinetics; warfarin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Algorithms
  • Anticoagulants / administration & dosage*
  • Anticoagulants / blood
  • Anticoagulants / pharmacokinetics*
  • Black or African American / genetics*
  • Body Surface Area
  • Body Weight
  • Cytochrome P-450 CYP2C9 / genetics*
  • Cytochrome P-450 CYP2C9 / metabolism*
  • Dose-Response Relationship, Drug
  • Female
  • Genotype
  • Humans
  • International Normalized Ratio
  • Male
  • Metabolic Clearance Rate / genetics
  • Middle Aged
  • Models, Biological
  • Polymorphism, Single Nucleotide
  • Vitamin K Epoxide Reductases / genetics
  • Warfarin / administration & dosage*
  • Warfarin / blood
  • Warfarin / pharmacokinetics*

Substances

  • Anticoagulants
  • Warfarin
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • VKORC1 protein, human
  • Vitamin K Epoxide Reductases